Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro
Titel:
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro
Auteur:
Zhu, Liancheng Lopez, Salvatore Bellone, Stefania Black, Jonathan Cocco, Emiliano Zigras, Tiffany Predolini, Federica Bonazzoli, Elena Bussi, Beatrice Stuhmer, Zachary Schwab, Carlton L. English, Diana P. Ratner, Elena Silasi, Dan-Arin Azodi, Masoud Schwartz, Peter E. Rutherford, Thomas J. Santin, Alessandro D.